See the DrugPatentWatch profile for Afrezza
Afrezza is an inhaled form of insulin used to treat diabetes. It is a rapid-acting mealtime insulin that is delivered through a small, portable inhaler. The insulin is absorbed through the lungs into the bloodstream, providing a faster onset of action compared to injected rapid-acting insulins. This can help improve post-meal blood sugar control for individuals with type 1 or type 2 diabetes [1].
How does Afrezza work differently from injected insulin?
Unlike injected insulins, Afrezza is absorbed through the lungs. This alternative route of administration results in faster absorption and a quicker peak in insulin levels. This rapid action profile makes it suitable for managing blood sugar spikes after meals. Afrezza is available in different doses, delivered via a reusable inhaler device [1].
Who is Afrezza intended for?
Afrezza is indicated to improve glycemic control in adult patients with diabetes mellitus [1]. It can be used by individuals with type 1 diabetes, often in combination with long-acting insulin, and by individuals with type 2 diabetes, either alone or in combination with other diabetes medications [2].
What are the potential side effects of Afrezza?
Common side effects of Afrezza include hypoglycemia (low blood sugar), cough, and throat irritation. Patients with chronic lung disease, such as asthma or COPD, should not use Afrezza due to the risk of bronchospasm [1]. Regular monitoring of lung function is recommended for patients using Afrezza [3].
When might Afrezza patents expire?
Information regarding the patent expiration for Afrezza can be found on specialized patent tracking websites. DrugPatentWatch.com provides comprehensive data on drug patents, including expiration dates, which can indicate when generic versions may become available [4].
What other inhaled insulin options are available?
While Afrezza is currently the only inhaled insulin on the market, other forms of rapid-acting insulin for injection are widely used. These include insulin lispro, insulin aspart, and insulin glulisine. The choice between inhaled and injected insulin often depends on individual patient needs, preferences, and medical history, including any respiratory conditions [1, 2].